期刊文献+

新型双核芳基钌配合物的合成、结构、抗癌活性及与DNA相互作用研究 被引量:2

Novel dinuclear arene ruthenium(Ⅱ) complexes:synthesis,structure,anticancer activity and interaction with DNA
原文传递
导出
摘要 本文使用柔性配体1,3-二(1-咪唑-亚甲基)-2,4,6-三甲基苯(m-bitmb)与对甲基异丙基芳基钌反应,合成了两种新型的M_2L_2双核环状芳基钌配合物[{Ru(η~6-p-cymene)}_2(m-bitmb)_2Cl_2](SbF_6)_2(1)和[{Ru(η~6-p-cymene)}_2(m-bitmb)_2Cl_2](CF_3COO)_2(2),通过单晶衍射、核磁共振波谱、质谱和元素分析等方法表-征了它们的结构,并用3-(4,5-二甲基噻唑-2)2,5-二苯基四氮唑溴盐(MTT)法、圆二色谱和琼脂糖凝胶电泳等方法研究了抗癌活性及其与DNA的相互作用.结果表明,两个配合物具有"椅式"构型;均具有一定的抗癌活性,其中2对HeLa细胞株有较强的杀伤作用;均可使CT-DNA、PBR322质粒DNA的构象发生变化,且2与DNA的作用较强,这与其抗癌活性结果相一致. Two new dinuclear Ru(Ⅱ) arene M2L2 metallocycle complexes[Ru2(η^6-p-cymene)2(m-bitmb)2Cl2](SbF6)2(1)and[Ru2(η^6-p-cymene)2(m-bitmb)2Cl2](CF3COO)2(2)(m-bitmb=1,3-bis(imidazol-l-ymethyl)-2,4,6-trimethylbenzene)were synthesized and characterized by single crystal X-ray diffraction,-1H NMR,ESI-MS and elemental analysis.Results revealed that complex 1 and 2 are M2L2 dinuclear Ru-arene complexes with unique "chair-like" conformation.Both of complexes 1 and 2 had certain anti-cancer activity,and complex 2 performed good cytotoxic effect on HeLa cells.The results of circular dichroism and agarose gel electrophoresis experiments indicated that complexes 1 and 2could change the conformation of CT-DNA and PRB322 DNA.Moreover,compared with 1,2 presented much stronger interaction with DNA,which was in accordance with their anti-cancer activities.
出处 《中国科学:化学》 CAS CSCD 北大核心 2017年第2期277-283,共7页 SCIENTIA SINICA Chimica
基金 国家自然科学基金重点国际合作项目(编号:21420102002) 国家自然科学基金(编号:21302094,21401105,21601088) 高等学校博士学科点专项科研基金联合资助项目 江苏省333工程人才专项基金 江苏省六大人才高峰-新医药人才项目和江苏省优势学科 江苏省科技支撑计划--社会发展项目(编号:BE2013716)资助
关键词 芳基钌 双核配合物 抗癌活性 晶体结构 DNA结合 ruthenium-arene dinuclear complex anticancer activity crystal structure DNA binding
  • 相关文献

参考文献1

二级参考文献60

  • 1Garcia M, Jemal A, Ward EM. Global Cancer Facts & Figures. Atalnta: American Cancer Society, 2007.
  • 2Rosenberg B, van Camp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature, 1969, 222: 385-386.
  • 3Liu HK, Sadler PJ. Metal complexes as DNA intercalators. Acc Chem Res, 2011, 44: 349-359.
  • 4Wong E, Giandomenico CM. Current status of platinum-based antitumor drugs. Chem Rev, 1999, 99: 2451-2466.
  • 5Galanski M, Jakupec MA, Keppler BK. Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem, 2005, 12: 2075-2094.
  • 6Yan YK, Melchart M, Habtemariam A, Sadler PJ. Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes. Chem Commun, 2005: 4764-4776.
  • 7Reedijk J. Metal-ligand exchange kinetics in platinum and ruthenium complexes. Platinum Met Rev, 2008, 52: 2-11.
  • 8Allardyce CS, Dyson PJ. Ruthenium in medicine: current clinical uses and future prospects. Platinum Met Rev, 2001, 45: 62-69.
  • 9Kostova I. Ruthenium complexes as anticancer agents. Curr Med Chem, 2006, 13: 1085-1107.
  • 10Pizarro AM, Habtemariam A, Sadler PJ. Activation mechanisms for organometallic anticancer complexes. Top Organomet Chem, 2010, 32: 21-56.

共引文献5

同被引文献8

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部